Invitrogen last week issued its fourth-quarter and full-year financial report for 2004, and restated its 2003 earnings calculations to comply with new accounting standards for public companies to report the potentially dilutitive effect of contingently convertible debt on earnings.

"It's a what-if analysis, showing what could happen," Steven Huddart, an accounting professor at Pennsylvania State University, told BioCommerce Week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.